Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 4/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3923863 | 0.94 | TACR1 (0.35) | TACR1GPR119SLC6A4KCNH2F2RL1 | |
| SCHEMBL2424815 | 0.91 | TACR1 (0.33) | TACR1GPR119SLC6A4KCNH2F2RL1 | |
| SCHEMBL3935599 | 0.90 | TACR1 (0.37) | TACR1SLC6A4KCNH2F2RL1CNR1 | |
| SCHEMBL2424992 | 0.89 | TACR1 (0.34) | TACR1GPR119SLC6A4KCNH2F2RL1 | |
| SCHEMBL2429799 | 0.87 | TACR1 (0.35) | TACR1SLC6A4KCNH2F2RL1CNR1 | |
| SCHEMBL2425604 | 0.87 | TACR1 (0.36) | TACR1SLC6A4KCNH2F2RL1CNR1 | |
| SCHEMBL2427061 | 0.87 | TACR1 (0.36) | TACR1GPR119SLC6A4KCNH2F2RL1 | |
| SCHEMBL2432268 | 0.87 | TACR1 (0.36) | TACR1SLC6A4KCNH2F2RL1CNR1 | |
| SCHEMBL2427186 | 0.87 | TACR1 (0.37) | TACR1SLC6A4KCNH2F2RL1CNR1 | |
| SCHEMBL3923286 | 0.86 | TACR1 (0.38) | TACR1SLC6A4KCNH2F2RL1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009009411-A1 | SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-15 | — | — | WO | disclosed |